Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas

This publication has 11 references indexed in Scilit:

• Phase I study of paclitaxel (P) combined with 14-day topotecan (T) Continuous IV (CIV) infusion in previously treated and untreated patients (PTS)
  European Journal Of Cancer, 1997
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
  Journal of Clinical Oncology, 1997
• Cancer statistics, 1997
  CA: A Cancer Journal for Clinicians, 1997
• Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas
  Investigational New Drugs, 1994
• Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro
  JNCI Journal of the National Cancer Institute, 1992
• DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
  Science, 1989
• Continuous 5-Fluorouracil (5FU) Infusion in Carcinoma of the Pancreas: A Phase II Study
  The Lancet Healthy Longevity, 1988
• A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric Carcinoma
  JAMA, 1985
• Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The gastrointestinal tumor study group
  Cancer, 1981
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958